NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ViroVet

ViroVet

Private
LeuvenHealthcare & Life Scienceshttps://www.virovet.com/

Last Round

Series C

Jun 16, 2022

Total Funding Raised

$24.05M

Company Overview

ViroVet is a biotechnology company that develops innovative technologies, including antiviral drugs and vaccines, for the control of viral diseases in livestock.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

animal healthveterinary biotechnologylivestock vaccinesantiviral drugsanimal pharmaveterinary medicinevaccine developmentsmall molecule therapeuticsepizootic disease controlbiotech licensingpreclinical researchanimal health techagritech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ViroVet Comparables

Compare ViroVet with similar companies based on industry and business-model similarity.

ViroVet comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VEROVACCiNES GmbH
81%
The Vaccine Group
80%
Genvax Technologies
78%

ViroVet Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJun 16, 2022
Series BMay 28, 2020
GrantSep 1, 2018
Series A ExtensionOct 4, 2017
Series AJan 10, 2017

Key People

Founding team and executive leadership

Stefaan Wera

Chief Operating Officer Co-founder

Founding Team

Erwin Blomsma

CEO And Co-founder

Founding Team

ViroVet Investors

Notable investors and investment history

ViroVet investors
InvestorRounds
Capricorn PartnersSeries B, Series C, Series A, Series A Extension
GimvSeries B, Series C
KU Leuven Research & Development (LRD)Series B, Series C
KU LeuvenSeries B, Series A
VIVES II - Louvain Technology FundSeries B, Series A
VLAIOGrant
VIVES PartnersSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 16, 2022

    Raised $8M from Gimv, Capricorn Partners, and others.

  • May 28, 2020

    $7M round led by Seventure Partners

ViroVet Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ViroVet Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ViroVet's valuation, stock price, and market status.

Firmographic Details

HeadquartersLeuven
Employee Range10
Year Founded2015
Last FundingJun 16, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.